Keynote speaker: Garry P. Nolan (Stanford University School of Medicine)Presented by the New York Academy of Sciences, the Myasthenia Gravis Foundation of America, and Blackwell Futura Media Services
Reported by William Check | Posted September 6, 2007
Myasthenia gravis (MG) is a neuromuscular disease characterized by fluctuating muscle weakness with fatigability. This weakness chiefly affects the oculofacial muscles and the proximal skeletal muscles. MG is marked by exacerbations and remission, and some patients experience severe, life-threatening weakness that can require intubation with mechanical ventilation. Myasthenia gravis is among the best understood autoimmune diseases and is one of the only ones—if not the only one—that fulfills strict criteria for autoimmunity.
Since 1954 the New York Academy of Sciences has been cosponsoring international conferences on MG as a way for researchers in this field to stay current with new developments and to exchange ideas. At the 2007 meeting researchers presented findings on a broad range of basic and clinical topics. This was a particularly dynamic conference, since many important advances have been made in the last several years regarding both pathogenesis and therapy.
Use the tabs above to find a meeting report and multimedia from this event.
Slide and audio presentations available from:
Chien-Ping Ko (University of Southern California)
Gil I. Wolfe (University of Texas Southwestern Medical Center)
Amelia Evoli (Catholic University, Rome)
Bruno Kyewski (German Cancer Research Center, Heidelberg)
Henry J. Kaminski (Saint Louis University)
Richard J. Barohn (University of Kansas Medical Center)
Johan A. Aarli (University of Bergen, Norway)
Donald B. Sanders (Duke University Medical Center)
Jon Sussman (Greater Manchester Neuroscience Centre)